BiotechTubeBiotechTube
Home/Pipeline/Xtandi (enzalutamide)

Xtandi (enzalutamide)

Prostate Cancer

ApprovedCommercial

Key Facts

Indication
Prostate Cancer
Phase
Approved
Status
Commercial
Company
Astellas Pharma

About Astellas Pharma

Astellas Pharma Inc. is one of Japan's leading pharmaceutical companies with a global presence, dedicated to turning innovative science into value for patients. The company has built a strong portfolio of prescription medicines and is advancing multiple programs through clinical development, with particular expertise in urology, oncology, immunology, and neuroscience. Astellas is committed to becoming a global biopharmaceutical company by leveraging external innovation and strategic partnerships.

View full company profile

Therapeutic Areas

UrologyOncologyImmunologyNeuroscienceNephrology

Other Prostate Cancer Drugs

DrugCompanyPhase
Erleada (apalutamide)Johnson & JohnsonApproved
Nubeqa (darolutamide)BayerApproved
Proxalutamide (HS-10370)Hansoh PharmaPhase 3
Darolutamide (Nubeqa)Orion CorporationApproved
Relacorilant + EnzalutamideCorcept TherapeuticsPhase 2
NBTXR3NanobiotixPhase 1/2
Praluzatamab ravtansine (CX-2009)CytomX TherapeuticsPhase 1/2
Bavdegalutamide (ARV-110)ArvinasPhase 2
ARV-766ArvinasPhase 2
Alpha DaRTAlpha Tau MedicalPhase 1/2
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials